Glass Jacobson Investment Advisors llc Has $39,000 Stake in Elevance Health, Inc. $ELV

Glass Jacobson Investment Advisors llc raised its position in shares of Elevance Health, Inc. (NYSE:ELV) by 400.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 100 shares of the company’s stock after acquiring an additional 80 shares during the quarter. Glass Jacobson Investment Advisors llc’s holdings in Elevance Health were worth $39,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the company. PKO Investment Management Joint Stock Co boosted its position in Elevance Health by 11.1% during the second quarter. PKO Investment Management Joint Stock Co now owns 4,000 shares of the company’s stock valued at $1,556,000 after acquiring an additional 400 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in Elevance Health by 10.1% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 935,044 shares of the company’s stock valued at $363,695,000 after acquiring an additional 85,590 shares during the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych boosted its position in shares of Elevance Health by 16.7% during the 2nd quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 700 shares of the company’s stock worth $272,000 after purchasing an additional 100 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Elevance Health during the 2nd quarter worth about $70,000. Finally, FSM Wealth Advisors LLC boosted its position in shares of Elevance Health by 20.8% during the 2nd quarter. FSM Wealth Advisors LLC now owns 842 shares of the company’s stock worth $328,000 after purchasing an additional 145 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Down 1.1%

ELV opened at $342.45 on Monday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.56 and a quick ratio of 1.56. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The firm has a market capitalization of $76.11 billion, a PE ratio of 14.00, a P/E/G ratio of 1.25 and a beta of 0.59. The company’s 50-day moving average is $327.09 and its 200 day moving average is $352.27.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Tuesday, October 21st. The company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.03 by $1.00. The firm had revenue of $50.09 billion during the quarter, compared to analyst estimates of $49.26 billion. Elevance Health had a net margin of 2.84% and a return on equity of 16.17%. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter last year, the business posted $8.37 EPS. As a group, research analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 19th. Stockholders of record on Friday, December 5th will be paid a dividend of $1.71 per share. The ex-dividend date is Friday, December 5th. This represents a $6.84 annualized dividend and a dividend yield of 2.0%. Elevance Health’s dividend payout ratio (DPR) is presently 27.96%.

Insider Activity

In related news, Director Susan D. Devore purchased 1,200 shares of the firm’s stock in a transaction dated Tuesday, August 19th. The stock was bought at an average price of $312.15 per share, for a total transaction of $374,580.00. Following the purchase, the director directly owned 3,502 shares in the company, valued at approximately $1,093,149.30. This trade represents a 52.13% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.29% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ELV shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Elevance Health in a research report on Friday. JPMorgan Chase & Co. cut their price objective on shares of Elevance Health from $472.00 to $384.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 22nd. Sanford C. Bernstein cut their price objective on shares of Elevance Health from $445.00 to $420.00 and set an “outperform” rating on the stock in a research report on Thursday, October 16th. Guggenheim increased their price objective on shares of Elevance Health from $360.00 to $398.00 and gave the stock a “buy” rating in a research report on Wednesday, October 8th. Finally, Leerink Partners reissued a “market perform” rating and set a $310.00 price objective (down previously from $510.00) on shares of Elevance Health in a research report on Friday, July 18th. Twelve equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, Elevance Health currently has an average rating of “Moderate Buy” and a consensus price target of $397.89.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.